America and China ended a three-day high level assembly with numerous results on intellectual property rights, including: local treatment of IP, trade secrets, geographical indications, inventor rights, patent info, sales of IP-intensive goods and services, on-line infringement, treatment of IP in standard-setting, bad faith brand filings, judicial finest practices, and licensing of technology, in line with America.

Other problems included market accessibility for brand name pharmaceuticals and medical goods, agricultural biotechnology and competition policy.

An overview of the results was circulated in a USTR “fact sheet.”

For example, it said an understanding was reached on “technology localization” for IP rights, saying:

“The Us and China give to make sure that both nations treat intellectual property rights owned or developed in other states the same as domestically owned or developed intellectual property rights. Businesses are free to base technology transfer choices on company and marketplace factors, and are free to independently negotiate and determine whether and under what conditions to assign or license intellectual property rights to unaffiliated or affiliated businesses. Both China and also the United States support the authorities has the right to take measures to support businesses to take part in research and development as well as the creation and protection of intellectual property rights.”